ß-thalassemia is caused by ß-globin gene mutations resulting in reduced (β+) or absent (β0) hemoglobin production. Patient life expectancy has recently increased, but the need for chronic transfusions in transfusion-dependent thalassemia (TDT) and iron chelation impairs quality of life1. Allogeneic hematopoietic stem cell (HSC) transplantation represents the curative treatment, with thalassemia-free survival exceeding 80%. However, it is available to a minority of patients and is associated with morbidity, rejection and graft-versus-host disease2. Gene therapy with autologous HSCs modified to express ß-globin represents a potential therapeutic option. We treated three adults and six children with ß0 or severe ß+ mutations in a phase 1/2 trial ( NCT02453477 ) with an intrabone administration of HSCs transduced with the lentiviral vector GLOBE. Rapid hematopoietic recovery with polyclonal multilineage engraftment of vector-marked cells was achieved, with a median of 37.5% (range 12.6-76.4%) in hematopoietic progenitors and a vector copy number per cell (VCN) of 0.58 (range 0.10-1.97) in erythroid precursors at 1 year, in absence of clonal dominance. Transfusion requirement was reduced in the adults. Three out of four evaluable pediatric participants discontinued transfusions after gene therapy and were transfusion independent at the last follow-up. Younger age and persistence of higher VCN in the repopulating hematopoietic cells are associated with better outcome.

Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia / S. Marktel, S. Scaramuzza, M.P. Cicalese, F. Giglio, S. Galimberti, M.R. Lidonnici, V. Calbi, A. Assanelli, M.E. Bernardo, C. Rossi, A. Calabria, R. Milani, S. Gattillo, F. Benedicenti, G. Spinozzi, A. Aprile, A. Bergami, M. Casiraghi, G. Consiglieri, N. Masera, E. D'Angelo, N. Mirra, R. Origa, I. Tartaglione, S. Perrotta, R. Winter, M. Coppola, G. Viarengo, L. Santoleri, G. Graziadei, M. Gabaldo, M.G. Valsecchi, E. Montini, L. Naldini, M.D. Cappellini, F. Ciceri, A. Aiuti, G. Ferrari. - In: NATURE MEDICINE. - ISSN 1078-8956. - 25:2(2019 Feb), pp. 234-241. [10.1038/s41591-018-0301-6]

Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia

S. Scaramuzza;A. Assanelli;A. Calabria;S. Gattillo;G. Graziadei;M.D. Cappellini;
2019

Abstract

ß-thalassemia is caused by ß-globin gene mutations resulting in reduced (β+) or absent (β0) hemoglobin production. Patient life expectancy has recently increased, but the need for chronic transfusions in transfusion-dependent thalassemia (TDT) and iron chelation impairs quality of life1. Allogeneic hematopoietic stem cell (HSC) transplantation represents the curative treatment, with thalassemia-free survival exceeding 80%. However, it is available to a minority of patients and is associated with morbidity, rejection and graft-versus-host disease2. Gene therapy with autologous HSCs modified to express ß-globin represents a potential therapeutic option. We treated three adults and six children with ß0 or severe ß+ mutations in a phase 1/2 trial ( NCT02453477 ) with an intrabone administration of HSCs transduced with the lentiviral vector GLOBE. Rapid hematopoietic recovery with polyclonal multilineage engraftment of vector-marked cells was achieved, with a median of 37.5% (range 12.6-76.4%) in hematopoietic progenitors and a vector copy number per cell (VCN) of 0.58 (range 0.10-1.97) in erythroid precursors at 1 year, in absence of clonal dominance. Transfusion requirement was reduced in the adults. Three out of four evaluable pediatric participants discontinued transfusions after gene therapy and were transfusion independent at the last follow-up. Younger age and persistence of higher VCN in the repopulating hematopoietic cells are associated with better outcome.
Adolescent; Adult; Bone and Bones; Child; Child, Preschool; Female; Hematopoietic Stem Cells; Humans; Male; Treatment Outcome; beta-Thalassemia; Blood Transfusion; Genetic Therapy; Hematopoietic Stem Cell Transplantation
Settore MED/09 - Medicina Interna
feb-2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
s41591-018-0301-6.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 7.26 MB
Formato Adobe PDF
7.26 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/648494
Citazioni
  • ???jsp.display-item.citation.pmc??? 86
  • Scopus 184
  • ???jsp.display-item.citation.isi??? 175
social impact